BATON ROUGE, La., Sept. 10 /PRNewswire/ -- Drug discovery and development
company Esperance Pharmaceuticals today announced that it has begun enrollment
and dosing of patients in a Phase 1 study of EP-100 in patients with advanced
solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic
Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting
peptide (tMDP) designed to seek and destroy cancer cells that over-express
luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH
receptors are over-expressed in a wide range of cancers including breast,
prostate, endometrial, pancreatic, ovarian, skin and testicular cancers.
